

Middlesex University Research Repository

An open access repository of

Middlesex University research

<http://eprints.mdx.ac.uk>

Wildeboer, Dirk ORCID logoORCID: <https://orcid.org/0000-0003-1298-7511>, Hill, K. E., Jeganathan, F., Williams, D. W., Riddell, A. D., Price, P. E., Thomas, D. W., Stephens, P., Abuknesha, Ramadan A. and Price, R. G. (2012) Specific protease activity indicates the degree of *Pseudomonas aeruginosa* infection in chronic infected wounds. *European Journal of Clinical Microbiology & Infectious Diseases*, 31 (9) . pp. 2183-2189. ISSN 0934-9723 [Article] (doi:10.1007/s10096-012-1553-6)

This version is available at: <https://eprints.mdx.ac.uk/8519/>

Copyright:

Middlesex University Research Repository makes the University's research available electronically.

Copyright and moral rights to this work are retained by the author and/or other copyright owners unless otherwise stated. The work is supplied on the understanding that any use for commercial gain is strictly forbidden. A copy may be downloaded for personal, non-commercial, research or study without prior permission and without charge.

Works, including theses and research projects, may not be reproduced in any format or medium, or extensive quotations taken from them, or their content changed in any way, without first obtaining permission in writing from the copyright holder(s). They may not be sold or exploited commercially in any format or medium without the prior written permission of the copyright holder(s).

Full bibliographic details must be given when referring to, or quoting from full items including the author's name, the title of the work, publication details where relevant (place, publisher, date), pagination, and for theses or dissertations the awarding institution, the degree type awarded, and the date of the award.

If you believe that any material held in the repository infringes copyright law, please contact the Repository Team at Middlesex University via the following email address:

eprints@mdx.ac.uk

The item will be removed from the repository while any claim is being investigated.

See also repository copyright: re-use policy: <http://eprints.mdx.ac.uk/policies.html#copy>

Abstract

Chronic non-healing wounds are a major health problem with resident bacteria strongly implicated in their impaired healing. A rapid-screen to provide detailed knowledge of wound bacterial populations would therefore be of value and help prevent unnecessary and indiscriminate use of antibiotics; a process associated with promoting antibiotic resistance. We analysed chronic wound fluid samples, which had been assessed for microbial content, using 20 different fluorimetric peptide substrates to determine whether protease activity correlated with the bacterial load. Eight of the peptide substrates showed significant release of fluorescence after reaction with some of the wound samples. Comparison of wound fluid protease activities with the microbiological data indicated that there was no correlation between bacterial counts and enzyme activity for most of the substrates tested. However, two of the peptide substrates produced a signal corresponding with the microbial data revealing a strong positive correlation with *Pseudomonas aeruginosa* numbers. This demonstrated that short fluorescent peptides can be used to detect protease activity in chronic wound fluid samples. The finding that two peptides were specific indicators for the presence of *P. aeruginosa* may be the basis for a diagnostic test to determine wound colonisation by this organism.

Keywords: chronic venous leg ulcer; AMC-peptides; *Staphylococcus aureus*; *Pseudomonas aeruginosa*; bacterial protease; chronic infection; skin wounds

1 **Introduction**

2 Chronic non-healing skin wounds are a major world health problem; occurring in
3 three main forms, pressure ulcers, venous leg ulcers and diabetic foot ulcers.
4 These wounds represent an unrecognised cause of disability and distress in the
5 aged population [1] and, importantly, are estimated to consume 2–4% of the
6 total healthcare budget in European Union countries [2, 3]. The incidence of
7 these wounds is rising inexorably with the increased age of the population and
8 corresponding increases in obesity and type II diabetes. These additional
9 comorbidities often result in lower limb amputations and sepsis as frequent
10 chronic wound complications. Uncertainty about the effectiveness of the
11 various wound dressings available [4] highlights the ambiguities involved in the
12 treatment of venous ulcers.

13 Whilst the aetiology of chronic wounds is multi-factorial, bacteria play an
14 important direct and indirect role in the chronicity of the disease [5]. Through
15 production of proteases and other metabolites, bacteria may both modulate
16 responses in the resident cellular populations and directly degrade extracellular
17 matrix. Additionally, bacteria also stimulate innate and adaptive inflammatory
18 responses in the dermis with the generation of oxidative stress in the wound
19 environment [6]. Wounds support a diverse microflora [7]. The importance of
20 anaerobic organisms in perpetuating wounds has been observed both *in vivo* [5,
21 8] and *in vitro* [6], although relatively few detailed microbiological studies have
22 been undertaken [9]. *Pseudomonas aeruginosa* and *Staphylococcus aureus*
23 are the most frequently isolated aerobic species from these wounds [5, 9]; both
24 species being opportunistic pathogens commonly found colonising healthy skin
25 [10]. *Staphylococcus aureus* can be highly pathogenic when invading the skin
26 barrier [11], and impairs wound-healing via the expression of a wide range of
27 virulence factors. In the wound environment, the formation of *P. aeruginosa*
28 biofilms results in significantly larger ulcers and delayed wound-healing [10] and
29 contributes to antibiotic resistance, particularly ciprofloxacin [12].

30 Rapid analysis of bacteria populating particular wounds would be extremely
31 useful in clinical practice, avoiding unnecessary and arbitrary use of antibiotics,
32 with its known promotion of antimicrobial resistance [13]. Unfortunately, current
33 microbiological analysis of wound fluid samples takes 48-72 h for aerobic
34 species and over 7 days for slow-growing strictly anaerobic bacteria.

1 Consequently, antibiotic prescribing for these patients is largely empirical with
2 the over-prescription of antibiotics [13] and antimicrobial resistance being a
3 common feature in these wounds [9].

4 Bacterial enzymes released into the local environment can be measured
5 using well established analytical processes based on chromogenic or
6 fluorogenic substrate assays. Proteases have great potential as specific
7 markers of infection. Novel approaches to infection treatment based on
8 proteases have been extensively researched [14, 15] with the emphasis being
9 on reducing protease activity in the wound using absorbent dressings [16, 17] or
10 protease inhibitors [18, 19]. Bacterial proteases released into the wound
11 environment have a variety of effects on defence and healing mechanisms.
12 These include the activation of matrix metalloproteinases (MMPs) by proteolytic
13 removal of the inhibitory pro-domains [20], targeting the fibrinolytic system [21]
14 and affecting macrophage activity [22]. Bacterially secreted endoproteases,
15 quantified using fluorescent peptide substrates, can be used for direct
16 identification of specific pathogenic bacteria [23]. Wildeboer *et al.* [23] showed
17 that protease activity, analysed using short peptide libraries, was most sensitive
18 and specific for the detection and quantification of *P. aeruginosa*. Hence,
19 characterising protease activity in wound fluid samples, with substrates that
20 specifically detect bacterial proteases, holds potential for a rapid diagnosis.

21 In the present study, the objective was to identify protease activity against
22 specific peptide substrates that correlated with the bacterial load of wound fluid
23 samples from patients with chronic infected wounds, particularly *P. aeruginosa*.

24 **Materials and Methods**

26 **Chemicals and reagents**

27 Chemicals and reagents, if not specified otherwise, were obtained from Sigma-
28 Aldrich (Poole, UK). Peptides were purchased from Sigma-Aldrich, Bachem
29 (St. Helens, UK), Biomol (Exeter, UK) and Calbiochem (Nottingham, UK).
30 Twenty different peptides labeled with a carboxy-terminal 7-amino-4-
31 methylcoumarin (AMC) were included in this study (Table 1).
32

33 **Patients**

1 Following local research ethics committee approval and after obtaining patient
2 informed written consent, patients with chronic venous leg ulceration attending
3 the Wound Healing Research Unit, University Hospital of Wales, Cardiff, UK
4 were recruited to provide swab and wound fluid samples. Patients were
5 selected that had highly exudating wounds and included four male and six
6 female patients (Table 2). The participant's ages ranged from 62 to 88 years,
7 with a mean age of 74.1 ± 9.2 years and wound duration ranging from 10
8 months to 27 years. The wounds were all located on the lower legs, with one a
9 malleolus wound, four semi-circumferential and five circumferential wounds.
10 Ulcer causation was venous disease in five cases, one burn, one trauma and
11 four of unknown aetiology. The patients were receiving a range of medication.
12 Three patients with infected wounds, assessed by experienced wound healing
13 experts, were taking oral antibiotics at the time of wound fluid sampling. Also of
14 note, participant 2 was also using potassium permanganate soaks, a topical
15 treatment effective against *Pseudomonas*.

16 17 **Wound fluid samples**

18 Wound fluid from patients was collected using a totally non-invasive method by
19 extracting the fluid from wound dressings [24]. At the same time, a
20 microbiological sample of the wound surface was obtained using Amies
21 charcoal transport swabs (Sterilin, Newport, UK). Samples were transported to
22 the microbiology laboratory where the wound fluid was eluted no later than 30
23 min after removal of the dressing from the wound. The dressings were cut into
24 5 cm x 5 cm squares placed in a sterile Petri-dish with 12.5 mL of wound fluid
25 elution buffer (0.1 M Tris-HCl, pH 7.4, 0.1% Triton X-100) and agitated on a tilt
26 board at 4°C for 4 h. The fluid was squeezed out of each dressing using sterile
27 forceps and the eluate of each dressing recombined in a sterile bottle. A 100
28 µL portion of this fluid was removed for microbial analysis. Wound fluid
29 samples were aliquoted and stored at -80°C in a locked Human Tissue
30 Authority approved freezer.

31 32 **Microbiological analysis of wound fluid samples**

33 Microbial swab samples were streaked onto non-selective media plates to
34 assess for the presence of bacteria in the wounds. Wound fluid samples were

1 extracted from dressings as described above, serially diluted in phosphate
2 buffered saline (137 mM NaCl, 3 mM KCl, 8 mM Na₂HPO₄, 1.5 mM KH₂PO₄, pH
3 7.4, PBS) and plated on to selective and non-selective media. *Pseudomonas*
4 agar (PA, LabM, Bury, UK) supplemented with 200 mg/L ceftriaxone and 15 mg/L
5 nalidixic acid was used for detection of *P. aeruginosa*, and colony identification
6 confirmed by colony morphology, Gram-stain, oxidase and catalase tests as
7 well as PCR. Mannitol salt agar (MSA, Oxoid, Basingstoke, UK) was used for
8 the detection of *S. aureus*. *Staphylococcus aureus* grow as yellow colonies on
9 MSA and identity was further confirmed by Gram-stain and coagulase tests.
10 Blood agar (BA, LabM, Bury, UK) was used for non-selective culture of the
11 whole microflora to obtain a total microbial count for each wound fluid sample.

13 **Protein quantification in wound fluid samples**

14 The total protein concentration of the wound fluid samples was quantified using
15 a BCA kit (Novagen–Merck, Darmstadt, Germany) following the standard
16 protocol for the micro-scale assay. The chronic wound fluid samples were
17 diluted 1:5 and 1:20 in Tris-buffered saline (137 mM NaCl, 10 mM Tris-HCl, pH
18 7.3, TBS) prior to assaying. Absorbance was measured at 584 nm in a micro-
19 plate reader (FLUOstar OPTIMA, BMG Labtech, Offenburg, Germany) and
20 analysed with the accompanying MARS software using a simultaneously
21 recorded bovine serum albumin reference curve.

23 **Fluorescent assay of protease activity with peptide-AMC substrates**

24 Peptide-AMC substrates were dissolved in DMSO at 5 mg/ml and diluted to 50
25 µM in PBS. Wound fluid samples were prepared as described above and
26 diluted prior to the assay with an equal volume of Tris buffered saline (137 mM
27 NaCl, 10 mM Tris, pH 7.3, TBS). Aliquots of 10 µl of 50 µM peptide-AMC were
28 pipetted into the wells of a black 96 well micro-titre plate (Greiner, Stonehouse,
29 UK) and 90 µl of wound fluid sample added. The final concentration of
30 substrates in the reaction mix was 5 µM. Fluorescence (excitation wavelength
31 355 nm, emission wavelength 450 nm) was measured at intervals from the start
32 of the reaction for 12 h following the addition of the wound fluid in a FLUOstar
33 OPTIMA plate reader. Measurements were taken at 5 min intervals for the first

1 h and then every 30 min. Results were corrected for the background fluorescence of the wound fluid sample, as well as for the peptide-AMC.

Results

Microbial status of the wound fluid samples

Pseudomonas aeruginosa was found to be present in all samples bar one, with limited growth seen in sample 1 (Table 2). Coagulase negative staphylococci (CNS) were found in six of the samples and *S. aureus* in five, with samples 3 and 4 containing both organisms. Other organisms detected included *Proteus* and *Corynebacterium* spp.

Total protein content of chronic wound fluid samples

The total protein concentration in the wound fluid samples ranged between 873 µg/mL and 510 µg/mL, with a mean of 697 µg/mL and a median of 719 µg/mL (Table 2). The total protein concentration did not correlate with any of the quantitative bacterial counts or protease activity detected with the fluorescent peptides.

Specific protease activity in wound fluid samples

Aliquots from ten chronic wound fluid samples (Table 2) were assayed with each of the peptide-AMC substrates (Table 1) to determine protease activity. Reaction and measurement conditions were optimised for maximum sensitivity and a rapid, but reliable response. Eight substrates out of the 20 tested showed a significant increase in fluorescence over the 12 h reaction time with all or some of the ten wound fluid samples. The slope of the initial linear phase was used to calculate enzyme activity against these eight substrates, as shown for samples numbers three and six (Fig. 1). Figure 2 shows a single point analysis of the fluorescence intensity after 1 h reaction time for all 10 wound fluid samples with the eight substrates showing the strongest response.

Analysis of protease activities obtained using the peptide-AMC substrates for a relationship with the microbiological data showed a positive correlation for initial enzyme activity, and for 60 min and 6 h signal intensity, with the microbial counts for *P. aeruginosa*. Scatter plots of all the data indicated that there was

no correlation between bacterial count and enzyme activity for most of the substrates. However, Pearson correlation analysis confirmed that enzyme activity measured with two of the 20 peptide-AMC substrates tested (VLK and AFK) were positively correlated with the *P. aeruginosa* quantitative microbial counts from the ten wound fluid samples ($p < 0.01$, $r > 0.8$, Table 3). There was only limited evidence for a moderate relationship between enzyme activity and *S. aureus* counts, and insufficient evidence for a relationship with total bacterial numbers (Table 3). Regression analysis of the 6 h data, using the AFK substrate with the ten wound fluid samples, revealed that enzyme activity against this substrate was a sufficient predictor of the number of *P. aeruginosa* found in the wound fluid sample ($R^2 = 72\%$, Fig. 3A) but not for *S. aureus* ($R^2 < 35\%$, Fig. 3B) or total number of bacteria (Fig. 3C).

Discussion

Bacterial proteases are a promising target for the analysis of infected wounds [25, 26] with the ultimate aim being to improve patient treatment regimes and overcome the limitations of currently employed antimicrobial therapies; often prescribed empirically. Previous work, using purified bacterial proteases and cultivated clinical isolates of *P. aeruginosa*, has shown that assays with specific peptide substrates can be used to rapidly quantify bacterial pathogens in a given sample [23]. Furthermore, recent identification and characterisation of proteases specific for pathogenic organisms [27, 28] holds possibilities for the development of more specific novel diagnostic approaches as a possible addition to currently employed microbiological and molecular methods. To achieve this goal, assays are required, which allow testing without the need for lengthy purification steps of the patient sample, and which then produce robust and rapid quantitative results.

The data presented showed that specific peptide substrates could be used to quantify protease activity in *ex vivo* samples from chronic infected wounds. We also demonstrated that rapid analysis could be directly achieved with these patient wound samples. However, only two of the wide range of peptide substrates screened, were identified as having efficacy as specific indicators for the presence of *P. aeruginosa* in wounds. None proved appropriate for detection of *S. aureus*.

1 Bacterial proteases play an important role in pathogenicity [29] and
2 *Pseudomonas* proteases have been shown to play a significant role in keratitis,
3 affecting both host defence and healing mechanisms [30]. Hence, profiling of
4 protease activity in a wound fluid sample could provide important information on
5 wound healing, particularly if wound proteases were measured over time.
6 Furthermore, the identification of species-specific substrates could be the first
7 step to developing specific inhibitory molecules that might limit the pathogenicity
8 of an infecting organism, not only by improving the host's ability to overcome
9 infection but also by promoting wound healing.

10 A number of the patients included in this study had received various forms of
11 treatment with bactericidal agents. However, five of the ten samples showed *P.*
12 *aeruginosa* counts of $> 1 \times 10^6$ cfu/mL; with the extracted wound fluid of only
13 one patient being negative for this organism. This implies that *P. aeruginosa*
14 remained largely unaffected by the antimicrobial treatment regimens being
15 used; highlighting the importance of specifically quantifying and targeting this
16 organism. Previous studies have shown that *P. aeruginosa* is often under
17 represented by microbial culture, being present in unculturable form [5].
18 Formation of biofilms by *P. aeruginosa* in infected wounds delayed healing in a
19 diabetic mouse model [31], demonstrating the importance of detecting and
20 targeting this organism in wound healing therapy.

21 Statistical analysis revealed a significant correlation for only two of the 20
22 substrates tested. The identified substrate, Suc-AFK-AMC, had previously
23 been shown to be a good marker for *P. aeruginosa* protease activity using
24 cultured reference strains [23]. The second positive substrate, Boc-VLK-AMC,
25 also cleaved the carboxy-terminal of a lysine residue, indicating that this may be
26 a key element in its substrate specificity. Further studies are needed to identify
27 the importance of the remaining peptide amino acids present and to explore the
28 possibility of increasing substrate-specificity by modification of these. Test
29 conditions in this study were optimised in such a way that significant results
30 could be obtained within a 1 h reaction time. Further testing of a larger number
31 of patient samples will be required to confirm these results, and to obtain further
32 insight into the effect that previous patient antimicrobial treatments may have on
33 test outcomes. Our results demonstrate that a rapid test, based on specific
34 enzyme activity, holds exciting potential for identifying pathogenic organisms

1 directly from patient samples such as wound fluid, without the need for time-
2 consuming processing or purification. Such systems could ultimately become
3 useful prognostic indicators of non-healing in the wound healing clinic and
4 hence a significant aid to patient treatment.

5 6 **Acknowledgements**

7 This work was funded by the Engineering and Physical Sciences Research
8 Council (EPSRC), grant number EP/D505445/1.

9 10 **References**

- 11 1. Siddiqui AR, Bernstein JM (2010) Chronic wound infection: Facts and
12 controversies. *Clin Dermatol* 28:519-526
- 13 2. Posnett J, Gottrup F, Lundgren H, Saal G (2009) The resource impact of
14 wounds on health-care providers in Europe. *J Wound Care* 18:154-161
- 15 3. Franks PJ, Flanagan M (2005) Innovations in wound care and The European
16 Wound Management Association. In: *The International Hospital Federation*
17 *Reference Book 2005/2006*. The International Hospital Federation, Ferney
18 Voltaire, France, pp 115-118
- 19 4. Palfreyman S, Nelson EA, Michaels JA (2007) Dressings for venous leg
20 ulcers: systematic review and meta-analysis. *BMJ* 335:244
- 21 5. Davies CE, Hill KE, Wilson MJ, Stephens P, Hill CM, Harding KG, Thomas
22 DW (2004) Use of 16S ribosomal DNA PCR and denaturing gradient gel
23 electrophoresis for analysis of the microfloras of healing and nonhealing
24 chronic venous leg ulcers. *J Clin Microbiol* 42:3549-57
- 25 6. Wall IB, Davies CE, Hill KE, Wilson MJ, Stephens P, Harding KG, Thomas
26 DW (2002) Potential role of anaerobic cocci in impaired human wound
27 healing. *Wound Repair Regen* 10:346-53
- 28 7. Bowler PG, Davies BJ (1999) The microbiology of infected and noninfected
29 leg ulcers. *Int J Dermatol* 38:573-8
- 30 8. Dowd SE, Wolcott RD, Sun Y, McKeethan T, Smith E, Rhoads D (2008)
31 Polymicrobial nature of chronic diabetic foot ulcer biofilm infections
32 determined using bacterial tag encoded FLX amplicon pyrosequencing
33 (bTEFAP). *PLoS one* 3:e3326
- 34 9. Davies CE, Hill KE, Newcombe RG, Stephens P, Wilson MJ, Harding KG,
35 Thomas DW (2007) A prospective study of the microbiology of chronic
36 venous leg ulcers to reevaluate the clinical predictive value of tissue
37 biopsies and swabs. *Wound Repair Regen* 15:17-22

- 1 10. Gjodsbol K, Christensen JJ, Karlsmark T, Jorgensen B, Klein BM, Krogfelt
2 KA (2006) Multiple bacterial species reside in chronic wounds: a
3 longitudinal study. *Int Wound J* 3:225-231
- 4 11. Yarwood JM, Schlievert PM (2003) Quorum sensing in *Staphylococcus*
5 infections. *J Clin Invest* 112:1620-1625
- 6 12. Walters MC, Roe F, Bugnicourt A, Franklin MJ, Stewart PS (2003)
7 Contributions of antibiotic penetration, oxygen limitation, and low metabolic
8 activity to tolerance of *Pseudomonas aeruginosa* biofilms to ciprofloxacin
9 and tobramycin. *Antimicrob Agents Chemother* 47:317-323
- 10 13. Howell-Jones RS, Price PE, Howard AJ, Thomas DW (2006) Antibiotic
11 prescribing for chronic skin wounds in primary care. *Wound Repair Regen*
12 14:387-93
- 13 14. Moali C, Hulmes DJS (2009) Extracellular and cell surface proteases in
14 wound healing: new players are still emerging. *Eur J Dermatol* 19:552-564
- 15 15. Toriseva M, Kahari VM (2009) Proteinases in cutaneous wound healing.
16 *Cell Mol Life Sci* 66:203-224
- 17 16. Shi L, Ermis R, Kiedaisch B, Carson D (2010) The effect of various wound
18 dressings on the activity of debriding enzymes. *Adv Skin Wound Care*
19 23:456-462
- 20 17. Motzkau M, Tautenhahn J, Lehnert H, Lobmann R (2011) Expression of
21 matrix-metalloproteases in the fluid of chronic diabetic foot wounds treated
22 with a protease absorbent dressing. *Exp Clin Endocrinol Diabetes* 119:286-
23 290
- 24 18. Stechmiller J, Cowan L, Schultz G (2010) The role of doxycycline as a
25 matrix metalloproteinase inhibitor for the treatment of chronic wounds. *Biol*
26 *Res Nurs* 11:336-344
- 27 19. Trengove NJ, Stacey MC, MacAuley S, Bennett N, Gibson J, Burslem F,
28 Murphy G, Schultz G (1999) Analysis of the acute and chronic wound
29 environments: the role of proteases and their inhibitors. *Wound Repair*
30 *Regen* 7:442-452
- 31 20. Okamoto T, Akaike T, Suga M, Tanase S, Horie H, Miyajima S, Ando M,
32 Ichinose Y, Maeda H (1997) Activation of human matrix metalloproteinases
33 by various bacterial proteinases. *J Biol Chem* 272:6059-6066
- 34 21. Beaufort N, Wojciechowski P, Sommerhoff CP, Szmyd G, Dubin G, Eick S,
35 Kellermann J, Schmitt M, Potempa J, Magdolen V (2008) The human
36 fibrinolytic system is a target for the staphylococcal metalloprotease
37 aureolysin. *Biochem J* 410:157-165
- 38 22. Smagur J, Guzik K, Bzowska M, Kuzak M, Zarebski M, Kantyka T, Walski
39 M, Gajkowska B, Potempa J (2009) Staphylococcal cysteine protease

- 1 staphopain B (SspB) induces rapid engulfment of human neutrophils and
2 monocytes by macrophages. *Biol Chem* 390:361-371
- 3 23. Wildeboer D, Jeganathan F, Price RG, Abuknesha RA (2009)
4 Characterization of bacterial proteases with a panel of fluorescent peptide
5 substrates. *Anal Biochem* 384:321-328
- 6 24. Cullen B, Smith R, McCulloch E, Silcock D, Morrison L (2002) Mechanism of
7 action of PROMOGRAN, a protease modulating matrix, for the treatment of
8 diabetic foot ulcers. *Wound Repair Regen* 10:16-25
- 9 25. Travis J, Potempa J (2000) Bacterial proteinases as targets for the
10 development of second-generation antibiotics. *Biochim Biophys Acta*
11 1477:35-50
- 12 26. Butler SM, Festa RA, Pearce MJ, Darwin KH (2006) Self-compartmentalized
13 bacterial proteases and pathogenesis. *Mol Microbiol* 60:553-62
- 14 27. Elston C, Wallach J, Saulnier J (2007) New continuous and specific
15 fluorometric assays for *Pseudomonas aeruginosa* elastase and LasA
16 protease. *Anal Biochem* 368:87-94
- 17 28. Stec-Niemczyk J, Pustelny K, Kisieleska M, Bista M, Boulware KT,
18 Stennicke HR, Thogersen IB, Daugherty PS, Enghild JJ, Baczynski K,
19 Popowicz GM, Dubin A, Potempa J, Dubin G (2009) Structural and
20 functional characterization of SplA, an exclusively specific protease of
21 *Staphylococcus aureus*. *Biochem J* 419:555-564
- 22 29. Wladyka B, Pustelny K (2008) Regulation of bacterial protease activity. *Cell*
23 *Mol Biol Lett* 13:212-229
- 24 30. Matsumoto K (2004) Role of bacterial proteases in pseudomonal and
25 serratal keratitis. *Biol Chem* 385:1007-1016
- 26 31. Zhao G, Hochwalt PC, Usui ML, Underwood RA, Singh PK, James GA,
27 Stewart PS, Fleckman P, Olerud JE (2010) Delayed wound healing in
28 diabetic (db/db) mice with *Pseudomonas aeruginosa* biofilm challenge: a
29 model for the study of chronic wounds. *Wound Repair Regen* 18:467-477

Tables

Table 1. Amino acid sequences of the 20 peptide-AMC substrates included in this study. Peptide amino acid sequences read from amino to the carboxy terminus, with all having a 7-amino-4-methylcoumaryl group (AMC) at the carboxy-terminus. Some of the peptides also carry a protective group at the α -amino group of their first amino acid.

No	Peptide substrate abbreviation
1	AAF-AMC
2	<i>Suc</i> -AAF-AMC ^a
3	Z-GGL-AMC ^b
4	Z-LLE-AMC ^b
5	<i>Suc</i> -AFK-AMC ^a
6	<i>Boc</i> -QAR-AMC ^c
7	<i>Boc</i> -VPR-AMC ^c
8	PFR-AMC
9	<i>Suc</i> -LLVY-AMC ^a
10	Z-RLRGG-AMC ^b
11	Z-AAN-AMC ^b
12	Z-GAM-AMC ^b
13	Z-GAH-AMC ^b
14	<i>Suc</i> -IIW-AMC ^a
15	<i>Boc</i> -VLK-AMC ^c
16	Z-GGR-AMC ^b
17	<i>Boc</i> -GKR-AMC ^c
18	<i>MeOSuc</i> -AAPV-AMC ^d
19	<i>Ac</i> -DEVD-AMC ^e
20	<i>Suc</i> -GPLGP-AMC ^a

^a *Suc*, succinyl

^b Z, carboxy benzoyl

^c *Boc*, tert. butyl-oxycarbonyl

^d *MeOSuc*, methoxy-succinyl

^e *Ac*, acetyl

1 **Table 2. Summary of key patient data, *P. aeruginosa* quantification and**
2 **total protein concentration in chronic wound fluid samples.** Concentration
3 values displayed are the mean of two independent measurements, each carried
4 out in triplicate.

5

Patient no.	Age (years)	Sex	Wound duration (months)	<i>Pseudomonas</i> sp. ^a (cfu/mL) ^b	Total protein (µg/mL)
1	88	M	36	limited growth	873
2	65	F	13	6.3 x 10 ⁶	783
3	84	M	216	6.5 x 10 ⁴	827
4	63	M	18	3.4 x 10 ⁹	717
5	68	F	216	4.5 x 10 ⁶	721
6	79	F	180	4.2 x 10 ⁶	563
7	80	F	10	n.d. ^c	562
8	62	F	48	4.8 x 10 ⁵	692
9	74	F	17	1.6 x 10 ⁴	720
10	78	M	138	7.8 x 10 ⁶	510

6 ^a counts derived from *Pseudomonas* agar plates

7 ^b cfu, colony forming units

8 ^c not detected

9


Table 3: Pearson correlation of protease activity in chronic wound fluid samples using two peptide-AMC substrates (VLK and AFK). Enzyme activity was measured as initial activity over 1 h and by single point analyses after 60 min and 6 h. Bacterial counts for *P. aeruginosa*, *Staphylococcus* spp. and CNS) and total bacteria, obtained from chronic wound swab sample cultures on selective (PA and MSA) and BA are also shown.

Peptidase activity with peptide-AMC		Pearson correlation	<i>P. aeruginosa</i>	<i>Staphylococcus</i> spp.	Total bacterial counts
VLK	initial rate	r^a	0.840	0.683	0.526
		p^b	0.009	0.043	0.118
	60 min	r^a	0.864	0.675	0.524
		p^b	0.006	0.046	0.120
	6 h	r^a	0.860	0.634	0.561
		p^b	0.006	0.066	0.091
	initial rate	r^a	0.794	0.658	0.514
		p^b	0.019	0.054	0.128
AFK	60 min	r^a	0.869	0.704	0.558
		p^b	0.005	0.034	0.094
	6 h	r^a	0.919	0.820	0.669
		p^b	0.001	0.007	0.035


^a r , Pearson correlation coefficient

^b p , probability value

1

2 **Figures**

3




4

5 **Fig. 1.** Initial protease activity plots for two selected wound fluid samples with
 6 the eight peptide-AMC substrates that showed the strongest response (A –
 7 patient sample 3, B – patient sample 6)

8


1




2

3 **Fig. 2.** Fluorescence intensity after 60 min reaction time of the wound fluid
 4 samples with the eight peptide-AMC substrates that showed the strongest
 5 response


6



1



2



1

2 **Fig. 3.** Regression analysis of quantitative bacterial counts for *P. aeruginosa*
 3 (A), *S. aureus* (B) and total bacterial count (C) with 6 h enzyme activity
 4 measured with Suc-AFK-AMC substrate

5